Using ontogeny information to build predictive models for drug elimination

Drug Discovery Today

Volumn 13, Issue 11-12, 2008, Pages 507-512

  Alcorn, Jane ^a   McNamara, Patrick J ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AGE DISTRIBUTION; ALLOMETRY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INFORMATION; HUMAN; MATHEMATICAL MODEL; ONTOGENY; REVIEW; RISK ASSESSMENT;

AGE FACTORS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 49949152544     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.016     Document Type: Review

References (57)

1. Cuzzolin L., et al. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin. Drug Saf. 5 (2006) 703-718
2. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin. Drug Saf. 3 (2004) 81-83
3. Baber N., and Pritchard D. Dose estimation for children. Br. J. Clin. Pharmacol. 56 (2003) 489-493
4. Ginsberg G., et al. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl. Pharmacol. 198 (2004) 164-183
5. Barton H.A. Computational pharmacokinetics during developmental windows of susceptibility. J. Toxicol. Environ. Health A 68 (2005) 889-900
6. McCarver D.G., and Hines R.N. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300 (2002) 361-366
7. Alcorn J., and McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin. Pharmacokinet. 41 (2002) 1077-1094
8. FDA, C. Guidance For Industry: General Considerations for Pediatric Pharmacokinetic Studies (http://www.Fda.Gov/Cder)
9. Kearns G.L., et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. New Engl. J. Med. 349 (2003) 1157-1167
10. Ginsberg G., et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66 (2002) 185-200
11. Kauffman R.E., and Kearns G.L. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin. Pharmacokinet. 23 (1992) 10-29
12. Ginsberg G., et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67 (2004) 297-329
13. Anderson B.J., et al. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33 (1997) 313-327
14. Johnson T.N. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol. 59 (2005) 663-669
15. Jullien V., et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother. 50 (2006) 3548-3555
16. Johnson T.N., et al. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45 (2006) 931-956
17. Mahmood I., and Balian J.D. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26 (1996) 887-895
18. Lee P.I. Design and power of a population pharmacokinetic study. Pharm. Res. 18 (2001) 75-82
19. Johnson T.N., et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br. J. Anaesth. 89 (2002) 428-437
20. Micallef S., et al. Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates. Clin. Pharmacokinet. 46 (2007) 59-74
21. Meibohm B., et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 7 (2005) E475-E487
22. Bjorkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods?. Clin. Pharmacokinet. 45 (2006) 1-11
23. Johnson, T.N. (2007) The problems in scaling adult drug doses to children. Arch. Dis. Child. published online 15 Mar 2007, doi:10.1136/adc.2006.114835
24. Hayton W.L. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS Pharm. Sci. 2 (2000) E3
25. Alcorn J., and McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41 (2002) 959-998
26. Edginton A.N., et al. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45 (2006) 683-704
27. Yang F., et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J. Pharmacokinet. Pharmacodyn. 33 (2006) 485-518
28. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br. J. Clin. Pharmacol. 61 (2006) 545-557
29. Holford N.H. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30 (1996) 329-332
30. Anderson B.J., and Meakin G.H. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr. Anaesth. 12 (2002) 205-219
31. Johnson T.N. A comparison of methods to predict drug clearance in neonates, infants and children. Br. J. Clin. Pharmacol. 57 (2004) 677-678
32. Edginton A.N., et al. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45 (2006) 1013-1034
33. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based PK modeling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59 (2004) 691-704
34. Price K., et al. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A 66 (2003) 417-433
35. Clewell R.A., et al. Perchlorate and radioiodide kinetics across life stages in the human: Using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J. Toxicol. Environ. Health A 70 (2007) 408-428
36. Nesterov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42 (2003) 883-908
37. Hines R.N. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert. Opin. Drug Metab. Toxicol. 2 (2006) 41-49
38. Hines R.N., and McCarver D.G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300 (2002) 355-360
39. de Wildt S.N., et al. Glucuronidation in humans. Pharmacogentic and developmental aspects. Clin. Pharmacokinet. 36 (1999) 439-452
40. Duanmu Z., et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J. Pharmacol. Exp. Ther. 316 (2006) 1310-1317
41. Miyagi S.J., and Collier A.C. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab. Dispos. 35 (2007) 1587-1592
42. Clewell H.J., et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79 (2004) 381-393
43. Nong A., et al. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 214 (2006) 78-87
44. McNamara P.J., and Alcorn J. Protein binding predictions in infants. AAPS Pharm Sci. 4 (2002) E4
45. Rudolph A.M. Hepatic and ductus venosus blood flows during fetal life. Hepatology 3 (1983) 254-258
46. Elbarbry F.A., et al. Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J. Biochem. Mol. Toxicol. 21 (2007) 41-50
47. Alcorn J., et al. Evaluation of the assumptions of an ontogeny model of rat hepatic cytochrome P450 activity. Drug Metab. Dispos. 35 (2007) 2225-2231
48. Cocking C., et al. Drug metabolism studies in the newborn infant and children using an oral erythromycin breath test. Paediatr. Perinat. Drug Ther. 7 (2006) 172-177
49. Allegaert K., et al. Urinary metabolites to assess in vivo ontogeny of hepatic drug metabolism in early neonatal life. Methods Find Exp. Clin. Pharmacol. 29 (2007) 251-256
50. Blake M.J., et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81 (2007) 510-516
51. Ratanasavanh D., et al. Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology 13 (1991) 1142-1151
52. Gentry P.R., et al. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38 (2003) 1-16
53. Kearns G.L., et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin. Pharmacol. Ther. 74 (2003) 413-422
54. Saldien V., et al. Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. Anesth. Analg. 97 (2003) 44-49 table of contents
55. Stephenson T. How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. 59 (2005) 670-673
56. Faustman E.M., et al. Mechanisms underlying Children's susceptibility to environmental toxicants. Environ. Health Perspect. 108 Suppl. 1 (2000) 13-21
57. Tabacova S.A., and Kimmel C.A. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Reprod. Toxicol. 15 (2001) 467-478